NCT05905497已完成1 期
A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Bemnifosbuvir in Healthy Adult Japanese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)
研究概览
简要总结
This study will assess the safety, tolerability and pharmacokinetics (PK) of Bemnifosbuvir in healthy adult Japanese subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
- •Females must have a negative pregnancy test at Screening and prior to dosing
- •Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2
- •Willing to comply with the study requirements and to provide written informed consent
- •The subject must have been born in Japan and have both parents and 4 grandparents of Japanese descent
- •The subject must have lived outside of Japan for no more than 10 years
排除标准
- •Pregnant or breastfeeding
- •Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19
- •Abuse of alcohol or drugs
- •Use of other investigational drugs within 28 days of dosing
- •Other clinically significant medical conditions or laboratory abnormalities
研究组 & 干预措施
Bemnifosbuvir (BEM)
Experimental
oral tablet
干预措施: Bemnifosbuvir (BEM) (Drug)
结局指标
主要结局
Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)
时间窗: Day 1, Day 5
Pharmacokinetics (PK) of BEM Area under the plasma concentration-time curve (AUC)
时间窗: Day 1, Day 5
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis BChronic HepatitisChronic Hep BChronic Hepatitis bHBVNCT06671093Tune Therapeutics, Inc.36
撤回
1 期
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer PatientsNeoplasmsNCT01974258Hoffmann-La Roche
已完成
1 期
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)NCT02966782AbbVie70
已完成
1 期
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)Head and Neck CancerNCT01911598Genentech, Inc.24
进行中（未招募）
1 期
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDACMetastatic Pancreatic CancerNCT06059001Peptomyc S.L.26